Aktienanalyse zu Trevi Therapeutics Inc (TRVI)TRVITrevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Trevi Therapeutics Inc appears to be a good buy right now due to its current price of $12.61, which is well below the analyst price targets of $20 to $36. The company has a strong cash position of approximately $319 million, ensuring operational stability into 2030, which supports its ongoing clinical trials and market competitiveness. However, the main risk is the negative earnings trend, with a projected EPS of -0.11 for Q2 2026, indicating continued losses in the near term.